<DOC>
	<DOCNO>NCT02581072</DOCNO>
	<brief_summary>The study 4 way cross-over study subject moderate severe acne vulgaris receive SB204 4 % , supratherapeutic dose SB204 ( either 8 12 % ) , moxifloxacillin ( positive control ) appropriate placebo match . SB204 apply topically upper back , upper chest , upper shoulder , face .</brief_summary>
	<brief_title>A Thorough ECG Study Subjects With Acne Vulgaris Treated With SB204</brief_title>
	<detailed_description />
	<mesh_term>Acne Vulgaris</mesh_term>
	<mesh_term>Moxifloxacin</mesh_term>
	<mesh_term>Norgestimate , ethinyl estradiol drug combination</mesh_term>
	<criteria>Moderate severe acne 20 inflammatory 25 noninflammatory acne lesion Pregnant , try become pregnant , nurse Known allergy component topical SB204 formulation</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>70 Years</maximum_age>
	<verification_date>June 2016</verification_date>
</DOC>